his press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Star Scientific, Inc. and its consolidated subsidiaries ( collectively, "The Company") has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties and contingencies include, without limitation, the challenges inherent in new product development initiatives, the uncertainties inherent in the progress of scientific research, the Company's ability to raise additional capital in the future necessary to maintain its business, potential disputes concerning the Company's intellectual property, risks associated with litigation regarding such intellectual property, potential delays in obtaining any necessary government approvals of the Company's low-TSNA tobacco products, market acceptance of the Company's new smokeless tobacco products, competition from companies with greater resources than the Company, the Company's decision not to join the Master Settlement Agreement ("MSA"), the effect of state statutes adopted under the MSA, and the Company's dependence on key employees and on its strategic relationships with Brown & Williamson Tobacco Corporation in light of its combination with RJ Reynolds Tobacco Company, Inc. The impact of potential litigation, if initiated against or by individual states that have adopted the MSA, could be materially adverse to the Company.
See additional discussion u
'/>"/>
SOURCE Star Scientific Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
China Sky One Medical, Inc. Receives Scientific Achievement Award2.
NVIDIA CUDA Technology Dramatically Advances the Pace of Scientific Research3.
Epitomics Appoints Dr. Zhiqiang An as Chief Scientific Officer4.
FDA Approves Boston Scientifics Express(R) SD Renal Stent System5.
Decision Biomarkers Inc Announces Formation of Scientific Advisory Board6.
BioInformatics, LLC Studies Effective Strategies for Scientific Publishing in a Web 2.0 World7.
Milestone Scientific to Showcase STA(TM) System at the Greater New York Dental Meeting in New York City8.
Boston Scientific to Participate in Piper Jaffray Health Care Conference9.
NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists10.
Recognized Dermatology Expert Dr. Zoe Draelos Joins Histogen Scientific Advisory Board11.
Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board